Compare Royal Bank of Canada (RY) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royal Bank of Canada vs State Street SPDR S&P Biotech ETF — how do they compare? Royal Bank of Canada trades at $210.37 (market cap $289.51B), while State Street SPDR S&P Biotech ETF trades at $154.46. The key difference: Royal Bank of Canada pays a 2.42% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| RY | XBI | |
|---|---|---|
Market Cap | $289.51B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $217.87 | $164.28 |
52-Week Low | $128.46 | $85.16 |
Dividend Yield | 2.42% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
